trimetrexate has been researched along with Carcinoma, Hepatocellular in 2 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harvey, WH | 1 |
| Fleming, TR | 1 |
| Goodman, PJ | 1 |
| Harvey, JH | 1 |
| Rivkin, SE | 1 |
| MacDonald, JS | 1 |
| Rhee, MS | 1 |
| Balinska, M | 1 |
| Bunni, M | 1 |
| Priest, DG | 1 |
| Maley, GF | 1 |
| Maley, F | 1 |
| Galivan, J | 1 |
1 trial available for trimetrexate and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Phase II study of trimetrexate in previously untreated patients with hepatocellular carcinoma. Southwest Oncology Group study 8712.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Drugs, Investigational; Female; Humans; I | 1993 |
1 other study available for trimetrexate and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Role of substrate depletion in the inhibition of thymidylate biosynthesis by the dihydrofolate reductase inhibitor trimetrexate in cultured hepatoma cells.
Topics: Carcinoma, Hepatocellular; Folic Acid; Liver Neoplasms; Pteroylpolyglutamic Acids; Quinazolines; Thy | 1990 |